NASDAQ:SLDB Solid Biosciences (SLDB) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free SLDB Stock Alerts $8.21 -0.18 (-2.15%) (As of 12:22 PM ET) Add Compare Share Share Today's Range$8.20▼$8.4250-Day Range$8.39▼$14.7552-Week Range$1.81▼$15.05Volume54,232 shsAverage Volume298,978 shsMarket Capitalization$315.10 millionP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Solid Biosciences alerts: Email Address Solid Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.6% Upside$17.50 Price TargetShort InterestHealthy3.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 17 Articles This WeekInsider TradingSelling Shares$4,772 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.68) to ($2.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.08 out of 5 starsMedical Sector166th out of 921 stocksBiological Products, Except Diagnostic Industry18th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingSolid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSolid Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Solid Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.01% of the float of Solid Biosciences has been sold short.Short Interest Ratio / Days to CoverSolid Biosciences has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Solid Biosciences has recently decreased by 12.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSolid Biosciences does not currently pay a dividend.Dividend GrowthSolid Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLDB. Previous Next 2.4 News and Social Media Coverage News SentimentSolid Biosciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Solid Biosciences this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows2 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Solid Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,772.00 in company stock.Percentage Held by Insiders13.63% of the stock of Solid Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Solid Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Solid Biosciences are expected to grow in the coming year, from ($2.68) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solid Biosciences is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Solid Biosciences is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSolid Biosciences has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Solid Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThis could mean the end of the U.S dollar…Experts say global conflict and escalated tensions could send the U.S. economy spiraling… Which is why elites and billionaire investors turn to physical precious metals in times like these.Download your FREE Precious Metals Guide Now. About Solid Biosciences Stock (NASDAQ:SLDB)Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Read More SLDB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLDB Stock News HeadlinesMay 23 at 1:02 AM | americanbankingnews.comBrokers Set Expectations for Solid Biosciences Inc.'s Q2 2024 Earnings (NASDAQ:SLDB)May 21 at 3:38 AM | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC WainwrightMay 20 at 3:40 PM | markets.businessinsider.comBuy Rating for Solid Biosciences Anchored on Robust Financials and Promising Clinical ProspectsMay 20 at 6:00 AM | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 18, 2024 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Price Target Cut to $18.00May 18, 2024 | americanbankingnews.comSolid Biosciences Inc. (NASDAQ:SLDB) to Post Q3 2024 Earnings of ($0.78) Per Share, William Blair ForecastsMay 17, 2024 | americanbankingnews.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by AnalystsMay 15, 2024 | msn.comSolid Biosciences reports Q1 resultsMay 15, 2024 | investorplace.comSLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024May 15, 2024 | globenewswire.comSolid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsMay 15, 2024 | americanbankingnews.comContrasting Solid Biosciences (NASDAQ:SLDB) & Century Therapeutics (NASDAQ:IPSC)May 2, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | seekingalpha.comBuy Solid Biosciences: Unpacking Its Main Value DriverApril 3, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | markets.businessinsider.comSolid Biosciences: FDA Grants Rare Pediatric Disease Designation For SGT-003April 1, 2024 | globenewswire.comSolid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003March 28, 2024 | msn.comWilliam Blair starts Solid Biosciences at outperformMarch 27, 2024 | finance.yahoo.comSolid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumMarch 24, 2024 | finance.yahoo.comSLDB Apr 2024 7.500 putMarch 19, 2024 | markets.businessinsider.comCautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid BiosciencesMarch 18, 2024 | markets.businessinsider.comSolid Biosciences (SLDB) Gets a Buy from BarclaysMarch 16, 2024 | finance.yahoo.comSLDB Sep 2024 17.500 callMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Solid Biosciences on Promising Pipeline and Financial StabilityMarch 13, 2024 | finanznachrichten.deSolid Biosciences Inc.: Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial ResultsMarch 13, 2024 | markets.businessinsider.comSolid Biosciences Stock Drops 4% Due To Wider Loss In Q4See More Headlines Receive SLDB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today5/23/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SLDB CUSIPN/A CIK1707502 Webwww.solidbio.com Phone(617) 337-4680FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$20.00 Low Stock Price Target$16.00 Potential Upside/Downside+108.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.94% Return on Assets-44.95% Debt Debt-to-Equity Ratio0.01 Current Ratio14.94 Quick Ratio14.94 Sales & Book Value Annual Sales$8.09 million Price / Sales39.80 Cash FlowN/A Price / Cash FlowN/A Book Value$5.49 per share Price / Book1.53Miscellaneous Outstanding Shares38,380,000Free Float33,148,000Market Cap$322.01 million OptionableOptionable Beta2.02 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Ian F. Smith A.C.A. (Age 58)C.P.A., Executive Chair Comp: $75kMr. Alexander G. Cumbo (Age 53)President, CEO & Director Comp: $918.55kMr. Ilan Ganot (Age 50)Co-founder, Strategic Advisor to the CEO & Director Comp: $847.87kMr. Kevin Tan C.F.A. (Age 46)CFO & Treasurer Comp: $607.18kMr. David Tyronne Howton Jr. (Age 52)J.D., COO, General Counsel & Secretary Comp: $648.88kMs. Annie GanotCo-Founder & Head of Patient AdvocacyMr. Paul Herzich (Age 46)Chief Technology Officer Dr. Jennifer Marlowe Ph.D. (Age 47)Chief Scientific Officer Ms. Allison Bogosian J.D.Senior Vice President of Human ResourcesDr. Jessie Hanrahan Ph.D. (Age 48)Chief Regulatory Officer More ExecutivesKey CompetitorsShattuck LabsNASDAQ:STTKImmutepNASDAQ:IMMPAcrivon TherapeuticsNASDAQ:ACRVCorbus PharmaceuticalsNASDAQ:CRBPProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Bought 904,160 shares on 5/17/2024Ownership: 11.438%Artal Group S.A.Bought 1,590,781 shares on 5/17/2024Ownership: 6.603%Bain Capital Life Sciences Investors LLCBought 904,160 shares on 5/16/2024Ownership: 10.657%Janus Henderson Group PLCBought 1,808,440 shares on 5/16/2024Ownership: 4.777%Vanguard Group Inc.Bought 920,404 shares on 5/10/2024Ownership: 3.287%View All Insider TransactionsView All Institutional Transactions SLDB Stock Analysis - Frequently Asked Questions Should I buy or sell Solid Biosciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLDB shares. View SLDB analyst ratings or view top-rated stocks. What is Solid Biosciences' stock price target for 2024? 6 analysts have issued 12-month price targets for Solid Biosciences' stock. Their SLDB share price targets range from $16.00 to $20.00. On average, they expect the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 112.6% from the stock's current price. View analysts price targets for SLDB or view top-rated stocks among Wall Street analysts. How have SLDB shares performed in 2024? Solid Biosciences' stock was trading at $6.14 at the beginning of 2024. Since then, SLDB stock has increased by 34.0% and is now trading at $8.23. View the best growth stocks for 2024 here. When is Solid Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our SLDB earnings forecast. How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc. (NASDAQ:SLDB) posted its earnings results on Wednesday, March, 13th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.01. What ETFs hold Solid Biosciences' stock? ETFs with the largest weight of Solid Biosciences (NASDAQ:SLDB) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco DWA SmallCap Momentum ETF (DWAS). When did Solid Biosciences' stock split? Solid Biosciences shares reverse split on the morning of Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX). When did Solid Biosciences IPO? Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. Who are Solid Biosciences' major shareholders? Solid Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (11.44%), Bain Capital Life Sciences Investors LLC (10.66%), Artal Group S.A. (6.60%), Janus Henderson Group PLC (4.78%) and Vanguard Group Inc. (3.29%). Insiders that own company stock include Alexander Cumbo, Carl Ashley Morris, David T Howton, Ilan Ganot, Jessie Hanrahan, Joel Solomon Zev Schneider, Kevin Tan, Paul Herzich and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Solid Biosciences? Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLDB) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersDividend-like income from non-dividend stocksUnstoppable ProsperityTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe most important AI company you've never heard ofManward PressBill Gates is all about this tiny $2 stockTimothy SykesTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon to Transform U.S. Economy? Porter & CompanyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.